logo
US approves AstraZeneca, Daiichi's treatment for lung cancer

US approves AstraZeneca, Daiichi's treatment for lung cancer

Deccan Herald24-06-2025
The Anglo-Swedish drugmaker on Tuesday said it would pay Daiichi $45 million in milestone-related considerations following the US approval.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

AstraZeneca Pharma pops 4% on CDSCO nod to import Durvalumab solution
AstraZeneca Pharma pops 4% on CDSCO nod to import Durvalumab solution

Business Standard

time6 hours ago

  • Business Standard

AstraZeneca Pharma pops 4% on CDSCO nod to import Durvalumab solution

AstraZeneca Pharma share price: Pharmaceutical company AstraZeneca Pharma share price was buzzing in trade on Wednesday, July 2, 2025, with the stock rising up to 3.83 per cent to an intraday high of ₹9,239.25 per share. At 12:31 PM, AstraZeneca Pharma share price continued to trade near day's high levels, up 3.28 per cent at ₹9,190. In comparison, BSE Sensex was trading 0.19 per cent lower at 83,535.28 levels. What triggered the up move in AstraZeneca Pharma share price? AstraZeneca Pharma shares rose after the company received regulatory approval to expand the use of its cancer drug Imfinzi (Durvalumab) in India. The Central Drugs Standard Control Organisation (CDSCO) granted permission to import and distribute Durvalumab Solution for Infusion (120 mg/2.4 ml and 500 mg/10 ml) for an additional indication. In an exchange filing, AstraZeneca Pharma said, 'This is to inform that AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India to import for sale and distribution of Durvalumab Solution for Infusion 120 mg/2.4 ml and 500 mg/10 ml (Brand name: Imfinzi) for an additional indication.' The new approval allows Durvalumab, in combination with carboplatin and paclitaxel, to be used as a first-line treatment for adults with primary advanced or recurrent endometrial cancer who are candidates for systemic therapy. This is followed by maintenance treatment with Durvalumab and olaparib in cases of mismatch repair proficient (pMMR) endometrial cancer. The development enables AstraZeneca Pharma to market the drug in India for the newly approved indication, subject to further statutory approvals, if required. Track Stock Market LIVE Updates About AstraZeneca Pharma AstraZeneca Pharma is a British-Swedish multinational pharmaceutical and biotechnology company, formed in 1999 through the merger of Sweden's Astra AB and Britain's Zeneca Group. The company is dedicated to developing and selling innovative medicines across various therapeutic areas, including cancer, cardiovascular diseases, gastrointestinal issues, infections, neuroscience, respiratory conditions, and inflammation. The company has had a major presence in India for 45 years. AstraZeneca Pharma India oversees manufacturing, sales, and marketing operations, while the company also gained global recognition for its role in developing the Oxford–AstraZeneca Covid-19 vaccine Leveraging data science and artificial intelligence (AI), AstraZeneca claims to boost the success rates and efficiency of its research and development (R&D) processes. The market capitalisation of AstraZeneca Pharma is ₹22,988.75 crore, according to BSE. The company falls under the BSE500 index. The 52-week high of AstraZeneca share price is ₹10,653.05, while its 52-week low is ₹6,222.35.

Europe's IPO Bankers Pin Hopes on Fall Window as Revival Falters
Europe's IPO Bankers Pin Hopes on Fall Window as Revival Falters

Mint

timea day ago

  • Mint

Europe's IPO Bankers Pin Hopes on Fall Window as Revival Falters

(Bloomberg) -- After the slowest first half for European initial public offerings in more than a decade, dealmakers are banking on several large transactions to reignite the market later this year. IPOs in the region have raised roughly $5.52 billion so far in 2025, a 60% decline from a year ago, according to data compiled by Bloomberg. Turmoil unleashed by President Donald Trump's tariffs froze the market for weeks, and while some firms have since launched offerings, others deferred or canceled debuts. Europe's IPO recovery since has trailed Asia and North America. But with new and postponed deals penciled in for the second half, advisers hope European offerings can recover at a time when investor interest in the region has been rekindled by the prospect of increased defense spending and fiscal stimulus. 'There are a handful of European IPOs lined up for September or October that are true landmark events,' said Martin Thorneycroft, global co-head of equity capital markets at Morgan Stanley. Private equity firm Hellman & Friedman is considering a listing of security company Verisure in Stockholm as soon as this year that could value the business at more than €20 billion ($23.5 billion) including debt, Bloomberg News has reported. German stock exchange operator Deutsche Boerse AG is mulling a potential $1 billion share sale for its unit ISS Stoxx GmbH as soon as the second half. 'The bigger tests for the European IPO market come post-Labor Day when we should see some jumbo transactions,' said Alex Watkins, co-head of international ECM at JPMorgan Chase & Co., referring to the early-September US holiday that traditionally marks the start of the fall window. He sees the market picking up globally in the second half, 'setting the stage for a stronger IPO year in 2026.' Smaller and mid-cap companies have made up the bulk of issuance over the last six months. The region's biggest offering came from Asker Healthcare Group AB in Sweden, which raised about 10 billion Swedish kronor ($1.05 billion) and has soared since its debut. Others have had a bumpier start as listed companies, with Spain's travel technology firm HBX Group International Plc still trading below its offering price after its transaction raised €748 million ($880 million). Some companies have shelved plans to debut, with German online car-parts retailer Autodoc SE postponing its Frankfurt IPO, though the offering drew enough demand to cover the deal. Glencore Plc-backed Cobalt Holdings Plc also decided not to move forward with a $230 million London float. Still, others are forging on with plans to go public before the summer lull. German medical technology firm Brainlab SE is set to debut this week after a Frankfurt IPO that's expected to raise €320 million, while Blackstone Inc.-backed casino operator Cirsa Enterprises SA announced plans for a Spanish listing. How these deals fare will be important for encouraging more issuers to come to market, according to Luca Erpici, co-head of ECM at Jefferies Financial Group Inc. for Europe, the Middle East and Africa. But, ultimately, the success of any IPO will hinge on its own merits more than market momentum. 'It really comes down to the quality of the business, valuation and offer size,' Erpici said, adding that adjusting the size of an IPO is one of the 'key levers' sellers are using to ensure deals go well. For example, Blackstone Inc. injected fresh cash into Cirsa before the IPO was announced by raising payment-in-kind debt. Its offering is now set to raise about €453 million, with the bulk of the proceeds going toward lowering its debt. While Europe has seen successful large IPOs in recent years, mid-sized companies have generally had a harder time going public. The rise of index-tracking funds has lured away some of the traditional buyers for IPOs, and the higher interest rates that followed the Covid-19 pandemic increased the pressure on private equity-backed companies that have taken on debt, reducing their appeal to investors. New offerings also have to contend with trade and geopolitical uncertainty. 'Volatility is here to stay, or at least more so than we have been used to, so markets are learning to live with that, and, selectively, companies will continue to come to market,' said Lyle Schwartz, senior managing director and EMEA ECM lead at Evercore Inc. Companies that postponed listing plans earlier in the year could test the market again in the coming months. German pharmaceutical firm Stada Arzneimittel AG had postponed its planned IPO in March and Nordic Capital's Noba Bank Group AB pushed back plans to launch an IPO into the second half of the year. Others like SMG Swiss Marketplace Group AG, the operator of online real estate portal ImmoScout24, could also list as soon as this year, Bloomberg News has reported. 'Many IPOs have been deferred to after the summer, so September will be the real benchmark for the IPO market,' said Gareth McCartney, global co-head of ECM at UBS Group AG. Still, there's a risk that deals slip into next year because of company developments and the potential for markets to shift. 'You can see five or six European IPOs coming after Labor Day, but I don't think we're going to see a massive wave,' said Andreas Bernstorff, head of ECM at BNP Paribas SA. 'It's also unsure whether all will end up coming this year because of issues like leverage, and a lot of clients are considering what to do.' More stories like this are available on

Ericsson begins commercial release of made-in-India network antenna from VVDN facility
Ericsson begins commercial release of made-in-India network antenna from VVDN facility

Time of India

time2 days ago

  • Time of India

Ericsson begins commercial release of made-in-India network antenna from VVDN facility

Swedish telecom gear maker Ericsson has started rolling out its first-ever made-in-India mobile network antenna from electronic contract manufacturer VVDN's facility, the company said on Monday. In April, Ericsson announced setting up Ericsson Antenna System (EAS) production in India in collaboration with VVDN Technologies . The facility was inaugurated by Union telecom minister Jyotiraditya Scindia . "This is more than the launch of a manufacturing unit-it marks the birth of a facility that will power the networks of tomorrow and connect millions across the globe. It demonstrates global confidence in India's capabilities and India's growing confidence in its future," Scindia said. VVDN is one of the electronic manufacturing services companies that is eligible for the telecom production-linked incentive scheme . Live Events "The new antenna is ready for commercial release in June, with international shipments starting in July. These antennas will be for both domestic operators and international customers," Ericsson India Managing Director Nitin Bansal said. Ericsson said that it is expanding its passive antenna manufacturing and engineering ecosystem in India -- building an end-to-end capability that includes local sourcing, production, and engineering, with solutions specifically designed to meet global and Indian network requirements. "With more than 50 per cent of antenna content now produced locally, Ericsson is entering the next phase: evolving its India-based engineering capabilities to support regional adaptation, accelerate innovation, and scale with global demand. Ericsson's advanced passive antennas are at the forefront of next-generation 5G infrastructure ," the statement said. This is the second manufacturing facility of Ericsson in India. The company has already partnered with Jabil Circuit to manufacture 4G and 5G radios, RAN Compute, and microwave products. Bansal said that the capacity being set up with VVDN is completely new. "It is a completely separate factory for antenna manufacturing, whereas Jabil manufactures 4G and 5G radios, RAN (radio access network) compute, and microwave products for Ericsson in Pune, India," he said. Bansal said Ericsson's investment in local production and engineering not only strengthens India's telecom infrastructure but also contributes to building a resilient, future-ready ecosystem.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store